Sorafenib: from literature to clinical practice.

Di Marco, V; De Vita, F; Koskinas, J; Semela, D; Toniutto, P; Verslype, C

Di Marco, V; De Vita, F; Koskinas, J; Semela, D; Toniutto, P; Verslype, C.

Affiliation

Di Marco V; Sezione di Gastroenterologia & Epatologia, Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Palermo, Italy. vito.dimarco@unipa.it

Ann Oncol ; 24 Suppl 2: ii30-7, 2013 Apr.

Article in En | MEDLINE | ID: mdl-23715941

Subject(s)

Antineoplastic Agents/therapeutic use; Carcinoma, Hepatocellular/drug therapy; Liver Neoplasms/drug therapy; Molecular Targeted Therapy; Niacinamide/analogs & derivatives; Phenylurea Compounds/therapeutic use; Protein Kinase Inhibitors/therapeutic use; Translational Research, Biomedical; Animals; Carcinoma, Hepatocellular/enzymology; Carcinoma, Hepatocellular/mortality; Carcinoma, Hepatocellular/pathology; Evidence-Based Medicine; Humans; Liver Neoplasms/enzymology; Liver Neoplasms/mortality; Liver Neoplasms/pathology; Neoplasm Staging; Niacinamide/adverse effects; Niacinamide/therapeutic use; Phenylurea Compounds/adverse effects; Randomized Controlled Trials as Topic; Risk Factors; Sorafenib; Time Factors; Treatment Outcome

Key words

adverse events; clinical practice; observational studies; randomized clinical trials; sorafenib

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylurea Compounds / Niacinamide / Carcinoma, Hepatocellular / Protein Kinase Inhibitors / Translational Research, Biomedical / Molecular Targeted Therapy / Liver Neoplasms / Antineoplastic Agents Type of study: Clinical_trials / Etiology_studies / Guideline / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2013 Document type: Article Affiliation country: Italy Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google